The incidence of iatrogenic pseudoaneurysm of the femoral artery is rising, with a reported current incidence of 7% if patients are investigated by ultrasound (1).
Treatment in the femoral arterial segment has evolved over the last decade from operative repair, through USGC and more recently to thrombin injection.
Surgical intervention for femoral pseudoaneurysm has been recommended in patients of increasing age, peripheral vascular disease and raised plasma liver enzymes on admission, all of which are significant independent predictive variables for pseudoaneurysm rupture. Surgical repair, however, may be associated with a lengthy procedure and significant morbidity (2). Conversely, conservative management may result in spontaneous thrombosis and may be advocated if the aneurysm is <2cm and the patient is not anticoagulated (1). USGC was first described in 1991, is cheap and simple and avoids ionising radiation. It is however, time consuming, may be painful and may be ineffectual in anticoagulated patients. A series comparing USGC and thrombin injection gave a 63% primary technical success for USGC versus 93% for thrombin injection. Thrombosis occurred within seconds of thrombin injection (requiring a mean of 300 units), while mean time to thrombosis in the USCG group was 37 minutes. A cost analysis showed that thrombin treatment results in considerable savings in vascular resource use but not in overall hospital expenditures (2).
Percutaneous injection of thrombin may be unprotected or protected by placement of an occlusion (or angioplasty) balloon across the neck of the pseudoaneurysm. This may prevent propogation of thrombus into the parent vessel, with in-situ thrombosis or distal embolisation. Although an effective method, balloon protection may be unnecessarily invasive. Subsequent series reporting unprotected thrombin injection have shown high technical success and low complication rates (1). The safety of unprotected thrombin injection depends on the speed of formation of stable thrombus at the desired site and the dimensions of the pseudoaneurysm neck. The communicating hole between pseudoaneurysm and parent vessel, being most commonly produced by a needle, is small, between 2-3mm (1). Native vessel occlusion during unprotected thrombin injection has been reported, but occurred in the situation of a wide neck (1). If no aneurysm neck is visible, or the neck is wider than a point source, USGC may be attempted, followed by balloon protected thrombin injection if compression fails. The status of the run-off is assessed clinically at completion by palpation of distal pulses and may be augmented by ankle pressures.
Since reports of its use in femoral pseudoaneurysm, percutaneous thrombin injection has been used in several peripheral arterial sites and for treatment of pseudoaneurysm of the pancreatic head.
To date, various treatment modalities have been proposed for graft-related pseudoaneurysm. Detachable balloons have been used to exclude pseudoaneurysm related to an upper extremity dialysis graft but this has not been shown to be a durable treatment. There has been some enthusiasm for covered-stent placement for graft related pseudoaneurysm. There have been mixed results. Two patients treated with PTFE-covered Palmaz stents had successful pseudoaneurysm exclusion and functioning grafts in the intermediate term (6 months) (3). Other reports of covered-stent placement have had less favourable outcomes. Two of 3 patients in whom placement of a Cragg Endo-Pro stent graft resulted in satisfactory pseudoaneurysm exclusion, developed recurrence in the intermediate term due to repeated stent-graft puncture during dialysis (4).
Thrombin dosage is titrated against effect- commonly up to 1500 units may be injected per pseudoaneurysm at any one time.
The origin of the thrombin should be considered. The commercially available forms are bovine and human, the latter usually released on a named-patient basis. There have been reports of antibody formation to bovine thrombin (1). Bovine thrombin may be used to promote haemostasis during vascular surgery, including dialysis-access. Patients may mount an antibody response to this and some may develop antiphospholipid antibodies. It may be argued that bovine thrombin should have been avoided in this case. Surgeons at our centre do not routinely use bovine thrombin during vascular access and human thrombin was unavailable. The bradycardiac event at completion of the procedure was thought to be vasovagal; the clinical manifestations and time frame were inconsistent with allergic reaction.